Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365490 | 0.88 | SRD5A2 (0.47) | SRD5A2SRD5A1ALDH1A1TTRPTPRC | |
| SCHEMBL12365357 | 0.88 | LMNA (0.39) | ALDH1A1RXRASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12365062 | 0.85 | SRD5A2 (0.47) | SRD5A2SRD5A1ALDH1A1TTRPTPRC | |
| SCHEMBL12366702 | 0.85 | HTR2B (0.46) | — | |
| SCHEMBL12390256 | 0.82 | SRD5A2 (0.44) | SRD5A2SRD5A1ALDH1A1TTRPTPRC | |
| SCHEMBL12365492 | 0.81 | SRD5A2 (0.43) | SRD5A2SRD5A1ALDH1A1TTRPTPRC | |
| SCHEMBL12365126 | 0.81 | RXRA (0.44) | SRD5A2SRD5A1ALDH1A1RXRARXRB | |
| SCHEMBL12364992 | 0.80 | SRD5A2 (0.49) | SRD5A2SRD5A1ALDH1A1TTRPTPRC | |
| SCHEMBL12389043 | 0.80 | AOC3 (0.43) | RXRARXRBRXRGPOLB | |
| SCHEMBL12365080 | 0.79 | SRD5A2 (0.50) | SRD5A2SRD5A1ALDH1A1TTRPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SRD5A2 412/4885SRD5A1 247/4885ALDH1A1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.